Angel Perez
Family Medicine · Wilmington, CANPI 1477654440
Payments from drug & device makers
Across 138 payments — averaging $21.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$435
- Johnson & Johnson$432
- Novo Nordisk$304
- Lilly USA, LLC$251
- Pfizer$167
- Boehringer Ingelheim$160
- plus $1K from 18 others
What the payments were for
- Food & beverage$2,909100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 17 | $435 |
| Johnson & Johnson | 17 | $432 |
| Novo Nordisk | 21 | $304 |
| Lilly USA, LLC | 13 | $251 |
| Pfizer | 6 | $167 |
| Boehringer Ingelheim | 7 | $160 |
| Amarin Pharma, Inc. | 7 | $157 |
| Bayer | 9 | $149 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $124 |
| Sumitomo Pharma America, Inc. | 4 | $117 |
| Almatica Pharma LLC | 5 | $105 |
| AbbVie(2 entities) | 5 | $93 |
| Phathom Pharmaceuticals, Inc. | 4 | $65 |
| Ironwood Pharmaceuticals, Inc | 3 | $63 |
| Merck | 3 | $50 |
| Astellas Pharma US Inc | 2 | $42 |
| Biohaven Pharmaceuticals, Inc. | 2 | $42 |
| Mannkind Corporation | 2 | $35 |
| Dexcom, Inc. | 1 | $24 |
| GSK | 1 | $24 |
| Esperion Therapeutics, Inc. | 1 | $21 |
| Amgen | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Metacel Pharmaceuticals LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$113
How this compares
$2,909 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 166 | $204,451 |
| JardianceEmpagliflozin | 97 | $136,369 |
| TradjentaLinagliptin | 89 | $105,916 |
| LinzessLinaclotide | 87 | $84,084 |
| OzempicSemaglutide | 53 | $60,737 |
| TrulicityDulaglutide | 58 | $57,602 |
| RybelsusSemaglutide | 33 | $57,117 |
| JanuviaSitagliptin Phosphate | 40 | $56,192 |
| EliquisApixaban | 47 | $46,765 |
| JanumetSitagliptin Phos/Metformin Hcl | 37 | $45,490 |
| TrintellixVortioxetine Hydrobromide | 53 | $44,017 |
| MounjaroTirzepatide | 37 | $42,991 |
| MyrbetriqMirabegron | 25 | $30,756 |
| XareltoRivaroxaban | 17 | $23,025 |
| Tresiba Flextouch U-200Insulin Degludec | 24 | $13,502 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $160 | $242,285186 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $435 | $213,961179 claims |
| Novo NordiskOzempic, Rybelsus | $304 | $117,85486 claims |
| MerckJanuvia, Janumet | $50 | $101,68277 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $251 | $100,59395 claims |
| AbbVieLinzess | $93 | $84,08487 claims |
| PfizerEliquis | $167 | $46,76547 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $124 | $44,01753 claims |
| Astellas Pharma US IncMyrbetriq | $42 | $30,75625 claims |
| Johnson & JohnsonXarelto | $432 | $23,02517 claims |
| GSKTrelegy Ellipta | $24 | $8,17815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.
Other family medicine in Wilmington
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.